Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials
| City: |
|
Orange |
| State: |
|
California |
| Zip Code: |
|
|
| Conditions: |
|
Eyelash Hypotrichosis - Alopecia Areata |
| Purpose: |
|
This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily
application to the upper eyelid margins compared with vehicle in treating eyelash loss or
hypotrichosis (inadequate or not enough eyelashes) in children.
|
| Study Summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Children who have inadequate eyelashes or have lost their eyelashes as a result of
chemotherapy treatment, who completed their chemotherapy (intensive treatment) at
least 4 weeks before starting the study, are considered to be at low risk for relapse
of their cancer, and are well enough to complete the study
- Children who have minimal to moderate inadequate eyelashes due to alopecia areata
- Adolescents between the ages of 15-17 years who have minimal to marked inadequate
eyelashes
Exclusion Criteria:
- Any eye disease or abnormality, eye surgery, permanent eyeliner, eyelash implants.
- Semi-permanent eyelash tint, dye or eyelash extension application within 3 months
- Use of over the counter eyelash growth products within 6 months.
- Use of prescription eyelash growth products (eg, Latisse®)
- Any eye condition that would prevent required ophthalmology exams
|
| NCT ID: |
|
NCT01023841 |
| Primary Contact: |
|
Study Director
Medical Director
Allergan
|
| Backup Contact: |
|
N/A |
| Location Contact: |
|
Orange, California
United States
There is no listed contact information for this specific location.
Site Status: N/A |
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
June 19, 2013 |
| Modifications to this listing: |
|
Only selected fields are shown, please use the link
below to view all information about this clinical trial. |
|
Click to view Full Listing
|